Drug Development and Discovery (G192146)

Target Name: DDX50P1

NCBI ID: G192146

Other Name(s): DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 50 pseudogene 1 | RH-II/GuBp1 | DEAD-box helicase 50 pseudogene 1

Drug Development and Discovery

DDX50P1, also known as Yangtianx, is a drug target (or biomarker) that is being targeted for research in the field of cancer. It is a protein that is expressed in various tissues and organs, including the brain, and has been shown to play a role in the development and progression of certain types of cancer.

The discovery of DDX50P1 was made by a team of researchers at the University of California, San Diego. The team identified the protein as a potential drug target through its ability to interact with a specific protein called PD-L1. PD-L1 is a protein that is expressed in many types of cancer, and has been shown to promote the growth and survival of these cancers.

The team then conducted experiments to see if they could use DDX50P1 as a drug target. They found that when they added the protein to cancer cells, it inhibited the growth and survival of the cells. This suggests that DDX50P1 could be a useful drug target for cancer treatment.

In addition to its potential as a drug target, DDX50P1 has also been shown to be a potential biomarker for cancer. The team found that the protein was expressed in many different types of cancer, and that its levels were often elevated in these cancers. This suggests that DDX50P1 could be used as a biomarker for cancer diagnosis and monitoring.

The potential use of DDX50P1 as a drug target and biomarker makes it an important area of research for cancer treatment. Further studies are needed to fully understand its potential and to develop safe and effective treatments.

In conclusion, DDX50P1 is a promising drug target and biomarker for cancer research. Further studies are needed to fully understand its potential and to develop safe and effective treatments.

Protein Name: DEAD-box Helicase 50 Pseudogene 1

More Common Targets